Adjuvant curcumin after prostate surgery to prevent cancer return
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 3 trial studies whether taking curcumin (a supplement made from turmeric) after radical prostatectomy can help keep prostate cancer from coming back. Participants are men with low-risk, surgery-only disease and undetectable PSA, and the study checks recurrence-free survival over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had radical prostatectomy (prostate removed) for confirmed prostate adenocarcinoma
- Your cancer stage is T1 to T3, but you do not have lymph node spread or metastases on tests
- Your PSA is undetectable at the start of the study
- You must be able to delay starting hormone or radiation treatment after surgery (no plan for adjuvant hormone or radiation)
- Surgery must have been no more than 3 months before you enroll
- You must have generally healthy kidneys, liver, and blood counts for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether curcumin (a supplement made from turmeric) can prevent low-risk prostate cancer from progressing while you stay on active surveillance. If you qualify, you would take curcumin and be monitored closely with regular checkups.
This Phase 2 study tests whether adding apalutamide to standard hormone therapy (ADT) after prostate surgery can lower the chance that prostate cancer comes back. It targets men at higher risk of recurrence based on PSA levels and a risk score from surgical findings.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
This trial studies whether hormone therapy (also called ADT) after prostate surgery lowers the chance that prostate cancer will return. It targets people with very low PSA after surgery but with a higher predicted risk of recurrence.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.